Patents by Inventor Manuela Mally

Manuela Mally has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240316172
    Abstract: A bioconjugate of an E. coli glucosylated O4 antigen polysaccharide covalently linked to a carrier protein and compositions thereof are provided. Also provided are recombinant host cells for producing the bioconjugate, and methods of producing the bioconjugate using the recombinant host cells. The recombinant host cells contain a nucleic acid encoding a glucosyl transferase capable of modifying the E. coli O4 antigen with glucose branching to produce the glucosylated O4 antigen polysaccharide. Bioconjugates of an E. coli glucosylated O4 antigen polysaccharide described herein can be used alone or in combination with one or more additional E. coli O-antigen polysaccharides to induce antibodies against an E. coli glucosylated antigen, and to vaccinate a subject against extra-intestinal pathogenic E. coli (ExPEC).
    Type: Application
    Filed: January 29, 2024
    Publication date: September 26, 2024
    Inventors: Jeroen GEURTSEN, Jan Theunis POOLMAN, Kellen Cristhina FAE, Pieter Jan BURGHOUT, Eveline Marleen WEERDENBURG, Patricia IBARRA YON, Darren Robert ABBANAT, Stefan Jochen KEMMLER, Michael Thomas KOWARIK, Manuela MALLY, Veronica GAMBILLARA FONCK, Martin Edward BRAUN, Maria Paula CARRANZA SANDMEIER
  • Patent number: 12076385
    Abstract: Compositions and methods are described for inducing an immune response against extra-intestinal pathogenic Escherichia coli (ExPEC) to thereby provide immune protection against diseases associated with ExPEC. In particular, compositions and methods are described for using conjugates of E. coli polysaccharide antigens O25B, O1A, O2, and O6A covalently bound to a detoxified exotoxin A of Pseudomonas aeruginosa (EPA) carrier protein as vaccines for the prevention of invasive ExPEC disease caused by ExPEC serotypes O1A, O2, O6A and O25B.
    Type: Grant
    Filed: September 23, 2022
    Date of Patent: September 3, 2024
    Assignees: Janssen Pharmaceuticals, Inc., GlaxosSmithKline Biologicals S.A.
    Inventors: Jan Theunis Poolman, Bert Jacquemyn, Darren Robert Abbanat, Patricia Ibarra Yon, Peter Wilhelmus Maria Hermans, Michael Thomas Kowarik, Michael Lukas Wetter, Stefan Jochen Kemmler, Micha Andres Häuptle, Veronica Gambillara Fonck, Manuela Mally
  • Publication number: 20240287568
    Abstract: Described herein are compositions and methods of producing glycosylated proteins in vitro and in vivo. The methods include using host cells to produce glycosylated proteins. Also described herein are glycosylated proteins produced using such methods and uses thereof.
    Type: Application
    Filed: January 4, 2024
    Publication date: August 29, 2024
    Inventors: Amirreza Faridmoayer, Manuela Mally, Rainer Follador
  • Patent number: 11931405
    Abstract: A bioconjugate of an E. coli glucosylated O4 antigen polysaccharide covalently linked to a carrier protein and compositions thereof are provided. Also provided are recombinant host cells for producing the bioconjugate, and methods of producing the bioconjugate using the recombinant host cells. The recombinant host cells contain a nucleic acid encoding a glucosyl transferase capable of modifying the E. coli O4 antigen with glucose branching to produce the glucosylated O4 antigen polysaccharide. Bioconjugates of an E. coli glucosylated O4 antigen polysaccharide described herein can be used alone or in combination with one or more additional E. coli O-antigen polysaccharides to induce antibodies against an E. coli glucosylated antigen, and to vaccinate a subject against extra-intestinal pathogenic E. coli (ExPEC).
    Type: Grant
    Filed: July 28, 2022
    Date of Patent: March 19, 2024
    Assignees: GlaxoSmithKline Biologicals S.A.
    Inventors: Jeroen Geurtsen, Jan Theunis Poolman, Kellen Cristhina Fae, Pieter Jan Burghout, Eveline Marleen Weerdenburg, Patricia Ibarra Yon, Darren Robert Abbanat, Stefan Jochen Kemmler, Michael Thomas Kowarik, Manuela Mally, Veronica Gambillara Fonck, Martin Edward Braun, Maria Paula Carranza Sandmeier
  • Publication number: 20240067714
    Abstract: The present disclosure provides monoclonal antibodies (e.g., anti-TNF? antibodies) having Fab sialylation, and, in some aspects, Fab sialylation in combination with an afucosylated Fc. Such antibodies having improved immunogenicity profiles and related advantages. Such glycan modifications will improve current treatments and allow a better quality of life for patients. Accordingly, such monoclonal antibodies are useful for treating and preventing various diseases.
    Type: Application
    Filed: September 13, 2021
    Publication date: February 29, 2024
    Applicant: LIMMATECH BIOLOGICS AG
    Inventors: Manuela MALLY, Amirreza FARIDMOAYER, Rainer FOLLADOR, Jonathan Albert BACK
  • Patent number: 11913051
    Abstract: Described herein are compositions and methods of producing glycosylated proteins in vitro and in vivo. The methods include using host cells to produce glycosylated proteins. Also described herein are glycosylated proteins produced using such methods and uses thereof.
    Type: Grant
    Filed: June 28, 2018
    Date of Patent: February 27, 2024
    Assignee: LimmaTech Biologics AG
    Inventors: Amirreza Faridmoayer, Manuela Mally, Rainer Follador
  • Publication number: 20230364214
    Abstract: Provided herein is an E. coli O polysaccharide, O25B. Also provided herein are prokaryotic host cells containing enzymes (e.g., glycosyltransferases) used in O25B production. The host cells provided herein produce O25B bioconjugates, wherein said bioconjugates contain O25B linked to a carrier protein. Further provided herein are compositions, e.g., pharmaceutical compositions, including O25B and/or bioconjugates containing O25B. Such compositions can be used as vaccines against infection with ExPEC, and may further include one or more additional bioconjugates.
    Type: Application
    Filed: April 24, 2023
    Publication date: November 16, 2023
    Inventors: Michael T. KOWARIK, Michael L. WETTER, Stefan J. KEMMLER, Micha A. HÄUPTLE, Veronica GAMBILLARA, Manuela MALLY
  • Publication number: 20230287327
    Abstract: The present application relates to Leishmania cells genetically engineered such that the formation of an O-linked GlcNAc on a polypeptide in the Leishmania cell is reduced or eliminated. The formation of the O-linked GlcNAc may be catalyzed in the Leishmania cell prior to said genetic engineering by at least one N-acetylglucosamine (GlcNAc)-transferase. Also provided herein are methods of making a polypeptide using a Leishmania cell described herein and polypeptides produced by the methods provided herein.
    Type: Application
    Filed: January 7, 2021
    Publication date: September 14, 2023
    Applicant: LIMMATECH BIOLOGICS AG
    Inventors: Manuela MALLY, Amirreza FARIDMOAYER, Rainer FOLLADOR, Anke Judith HARSMAN
  • Patent number: 11738076
    Abstract: Provided herein is an E. coli O polysaccharide, O25B. Also provided herein are prokaryotic host cells containing enzymes (e.g., glycosyltransferases) used in O25B production. The host cells provided herein produce O25B bioconjugates, wherein said bioconjugates contain O25B linked to a carrier protein. Further provided herein are compositions, e.g., pharmaceutical compositions, including O25B and/or bioconjugates containing O25B. Such compositions can be used as vaccines against infection with ExPEC, and may further include one or more additional bioconjugates.
    Type: Grant
    Filed: February 2, 2021
    Date of Patent: August 29, 2023
    Inventors: Michael T. Kowarik, Michael L. Wetter, Stefan J. Kemmler, Micha A. Häuptle, Veronica Gambillara, Manuela Mally
  • Publication number: 20230190926
    Abstract: Methods of producing bioconjugates of O-antigen polysaccharides covalently linked to a carrier protein using recombinant host cells are provided. The recombinant host cells used in the methods described herein encode a particular oligosaccharyl transferase enzyme depending on the O-antigen polysaccharide bioconjugate to be produced. The oligosaccharyl transferase enzymes can be PglB oligosaccharyl transferase or variants thereof. Also provided are compositions containing the bioconjugates, and methods of using the bioconjugates and compositions described herein to vaccinate a subject against extra-intestinal pathogenic E. coli. (ExPEC).
    Type: Application
    Filed: October 6, 2022
    Publication date: June 22, 2023
    Inventors: Jeroen GEURTSEN, Pieter Jan BURGHOUT, Eveline Marleen WEERDENBURG, Jan Theunis POOLMAN, Kellen Cristhina FAE, Patricia IBARRA YON, Darren Robert ABBANAT, Stefan Jochen KEMMLER, Michael Thomas KOWARIK, Manuela MALLY, Veronica GAMBILLARA FONCK, Martin Edward BRAUN, Maria Paula CARRANZA SANDMEIER
  • Publication number: 20230118878
    Abstract: A bioconjugate of an E. coli glucosylated O4 antigen polysaccharide covalently linked to a carrier protein and compositions thereof are provided. Also provided are recombinant host cells for producing the bioconjugate, and methods of producing the bioconjugate using the recombinant host cells. The recombinant host cells contain a nucleic acid encoding a glucosyl transferase capable of modifying the E. coli O4 antigen with glucose branching to produce the glucosylated O4 antigen polysaccharide. Bioconjugates of an E. coli glucosylated O4 antigen polysaccharide described herein can be used alone or in combination with one or more additional E. coli O-antigen polysaccharides to induce antibodies against an E. coli glucosylated antigen, and to vaccinate a subject against extra-intestinal pathogenic E. coli (ExPEC).
    Type: Application
    Filed: July 28, 2022
    Publication date: April 20, 2023
    Inventors: Jeroen GEURTSEN, Jan Theunis POOLMAN, Kellen Cristhina FAE, Pieter Jan BURGHOUT, Eveline Marleen WEERDENBURG, Patricia IBARRA YON, Darren Robert ABBANAT, Stefan Jochen KEMMLER, Michael Thomas KOWARIK, Manuela MALLY, Veronica GAMBILLARA FONCK, Martin Edward BRAUN, Maria Paula CARRANZA SANDMEIER
  • Publication number: 20230062987
    Abstract: Compositions and methods are described for inducing an immune response against extra-intestinal pathogenic Escherichia coli (ExPEC) to thereby provide immune protection against diseases associated with ExPEC. In particular, compositions and methods are described for using conjugates of E. coli polysaccharide antigens O25B, O1A, O2, and O6A covalently bound to a detoxified exotoxin A of Pseudomonas aeruginosa (EPA) carrier protein as vaccines for the prevention of invasive ExPEC disease caused by ExPEC serotypes O1A, O2, O6A and O25B.
    Type: Application
    Filed: September 23, 2022
    Publication date: March 2, 2023
    Inventors: Jan Theunis POOLMAN, Bert JACQUEMYN, Darren Robert ABBANAT, Patricia Ibarra YON, Peter Wilhelmus Maria HERMANS, Michael Thomas KOWARIK, Michael Lukas WETTER, Stefan Jochen KEMMLER, Micha Andres HÄUPTLE, Veronica Gambillara FONCK, Manuela MALLY
  • Publication number: 20230048847
    Abstract: The present application relates to a method of recombinantly engineering a Leishmania cell that involves homologous recombination of DNA fragments. Further provided herein are Leishmania cells recombinantly engineered using the method provided herein. Also provided herein are methods of making a polypeptide using a Leishmania cell described herein and polypeptides produced by the methods provided herein.
    Type: Application
    Filed: January 7, 2021
    Publication date: February 16, 2023
    Applicant: LIMMATECH BIOLOGICS AG
    Inventors: Manuela MALLY, Amirreza FARIDMOAYER, Fabio SERVENTI, Rainer FOLLADOR, Anke Judith HARSMAN
  • Patent number: 11491220
    Abstract: Methods of producing bioconjugates of O-antigen polysaccharides covalently linked to a carrier protein using recombinant host cells are provided. The recombinant host cells used in the methods described herein encode a particular oligosaccharyl transferase enzyme depending on the O-antigen polysaccharide bioconjugate to be produced. The oligosaccharyl transferase enzymes can be PglB oligosaccharyl transferase or variants thereof. Also provided are compositions containing the bioconjugates, and methods of using the bioconjugates and compositions described herein to vaccinate a subject against extra-intestinal pathogenic E. coli. (ExPEC).
    Type: Grant
    Filed: March 18, 2020
    Date of Patent: November 8, 2022
    Assignees: Janssen Pharmaceuticals, Inc.
    Inventors: Jeroen Geurtsen, Pieter Jan Burghout, Eveline Marleen Weerdenburg, Jan Theunis Poolman, Kellen Cristhina Fae, Patricia Ibarra Yon, Darren Robert Abbanat, Stefan Jochen Kemmler, Michael Thomas Kowarik, Manuela Mally, Veronica Gambillara Fonck, Martin Edward Braun, Maria Paula Carranza Sandmeier
  • Patent number: 11484582
    Abstract: Compositions and methods are described for inducing an immune response against extra-intestinal pathogenic Escherichia coli (ExPEC) to thereby provide immune protection against diseases associated with ExPEC. In particular, compositions and methods are described for using conjugates of E. coli polysaccharide antigens O25B, O1A, O2, and O6A covalently bound to a detoxified exotoxin A of Pseudomonas aeruginosa (EPA) carrier protein as vaccines for the prevention of invasive ExPEC disease caused by ExPEC serotypes O1A, O2, O6A and O25B.
    Type: Grant
    Filed: February 4, 2020
    Date of Patent: November 1, 2022
    Assignees: Janssen Pharmaceuticals, Inc.
    Inventors: Jan Theunis Poolman, Bert Jacquemyn, Darren Robert Abbanat, Patricia Ibarra Yon, Peter Wilhelmus Maria Hermans, Michael Thomas Kowarik, Michael Lukas Wetter, Stefan Jochen Kemmler, Micha Andres Häuptle, Veronica Gambillara Fonck, Manuela Mally
  • Patent number: 11446370
    Abstract: A bioconjugate of an E. coli glucosylated O4 antigen polysaccharide covalently linked to a carrier protein and compositions thereof are provided. Also provided are recombinant host cells for producing the bioconjugate, and methods of producing the bioconjugate using the recombinant host cells. The recombinant host cells contain a nucleic acid encoding a glucosyl transferase capable of modifying the E. coli O4 antigen with glucose branching to produce the glucosylated O4 antigen polysaccharide. Bioconjugates of an E. coli glucosylated O4 antigen polysaccharide described herein can be used alone or in combination with one or more additional E. coli O-antigen polysaccharides to induce antibodies against an E. coli glucosylated antigen, and to vaccinate a subject against extra-intestinal pathogenic E. coli (ExPEC).
    Type: Grant
    Filed: March 18, 2020
    Date of Patent: September 20, 2022
    Assignees: Janssen Pharmaceuticals, Inc., GlaxoSmithKline Biologicals S.A.
    Inventors: Jeroen Geurtsen, Jan Theunis Poolman, Kellen Cristhina Fae, Pieter Jan Burghout, Eveline Marleen Weerdenburg, Patricia Ibarra Yon, Darren Robert Abbanat, Stefan Jochen Kemmler, Michael Thomas Kowarik, Manuela Mally, Veronica Gambillara Fonck, Martin Edward Braun, Maria Paula Carranza Sandmeier
  • Publication number: 20220242919
    Abstract: Described herein are methods of producing glycosylated proteins in vitro and in vivo. The methods include using host cells to produce glycosylated proteins. Also described herein are glycosylated proteins produced using such methods and uses thereof.
    Type: Application
    Filed: December 17, 2021
    Publication date: August 4, 2022
    Inventors: Michael L. Wetter, Michael T. Kowarik, Amirreza Faridmoayer, Manuela Mally, Christian A. Lizak, Markus Aebi, Chia-wei Lin, Ivan Hang, Timothy Keys
  • Patent number: 11236136
    Abstract: Described herein are methods of producing glycosylated proteins in vitro and in vivo. The methods include using host cells to produce glycosylated proteins. Also described herein are glycosylated proteins produced using such methods and uses thereof.
    Type: Grant
    Filed: November 30, 2016
    Date of Patent: February 1, 2022
    Assignees: LIMMATECH BIOLOGICS AG, EIDGENÖSSISCHE TECHNISCHE HOCHSCHULE ZÜRICH
    Inventors: Michael L. Wetter, Michael T. Kowarik, Amirreza Faridmoayer, Manuela Mally, Christian A. Lizak, Markus Aebi, Chia-wei Lin, Ivan Hang, Timothy Keys
  • Publication number: 20210332403
    Abstract: Described herein are compositions and methods of producing glycosylated proteins in vitro and in vivo. The methods include using host cells to produce glycosylated proteins. Also described herein are glycosylated proteins produced using such methods and uses thereof.
    Type: Application
    Filed: June 28, 2018
    Publication date: October 28, 2021
    Inventors: Amirreza Faridmoayer, Manuela Mally, Rainer Follador
  • Publication number: 20210154286
    Abstract: Provided herein is an E. coli O polysaccharide, O25B. Also provided herein are prokaryotic host cells containing enzymes (e.g., glycosyltransferases) used in O25B production. The host cells provided herein produce O25B bioconjugates, wherein said bioconjugates contain O25B linked to a carrier protein. Further provided herein are compositions, e.g., pharmaceutical compositions, including O25B and/or bioconjugates containing O25B. Such compositions can be used as vaccines against infection with ExPEC, and may further include one or more additional bioconjugates.
    Type: Application
    Filed: February 2, 2021
    Publication date: May 27, 2021
    Inventors: Michael T. KOWARIK, Michael L. WETTER, Stefan J. KEMMLER, Micha A. HÄUPTLE, Veronica GAMBILLARA, Manuela MALLY